Mammalian MYC Proteins and Cancer
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
The MYC family of proteins is a group of basic-helix-loop-helix-leucine zipper transcription factors that feature prominently in cancer. Overexpression of MYC is observed in the vast majority of human malignancies and promotes an extraordinary set of changes that impact cell proliferation, growth, metabolism, DNA replication, cell cycle progression, cell adhesion, differentiation, and metastasis. The purpose of this review is to introduce the reader to the mammalian family of MYC proteins, highlight important functional properties that endow them with their potent oncogenic potential, describe their mechanisms of action and of deregulation in cancer cells, and discuss efforts to target the unique properties of MYC, and of MYC-driven tumors, to treat cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“The role of ARF-MDM2-p53-mediated apoptosis in combatting the tumorigenic potential of MYC is reflected in the frequent loss of p53 in human cancers [190] and evidenced by data from mouse model systems showing that loss of this pathway collaborates with MYC to drive oncogenesis [191, 192] and that certain tumor-derive…”
BackgroundWang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Gao, P., Tchernyshyov, I., Chang, T.-C., Lee, Y.-S., Kita, K., Ochi, T., Zeller, K. I., De Marzo, A. M., Van Eyk, J. E., Mendell, J. T., et al. (2009) · Nature · doi:10.1038/nature07823 · Cited by 2,124
Wise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001 · cited 1×
“In a similar vein, MYC-transformed cells also have a profound appetite for glutamine and enhanced glutamine metabolism [210], again mediated by MYC-driven changes in the expression of key metabolic enzymes [210, 211] and again converting cells to a state in which they become addicted to glutamine for their survival [2…”
BackgroundXTcf-3 Transcription Factor Mediates β-Catenin-Induced Axis Formation in Xenopus Embryos
Molenaar, M., van de Wetering, M., Oosterwegel, M., Peterson-Maduro, J., Godsave, S., Korinek, V., Roose, J., Destrée, O., & Clevers, H. (1996) · Cell · doi:10.1016/s0092-8674(00)80112-9 · Cited by 1,824
Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA
STEHELIN, D., VARMUS, H. E., BISHOP, J. M., & VOGT, P. K. (1976) · Nature · doi:10.1038/260170a0 · Cited by 1,321 · cited 1×
“of retroviral oncogenes [18].”
Ruley, H. E. (1983) · Nature · doi:10.1038/304602a0 · Cited by 1,248 · cited 1×
“and the need for this process to be overcome in cancer underlies the phenomenon of oncogene cooperation [24] and the now familiar concept that multiple genetic perturbations are required for tumor development [174].”
BackgroundMyc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245 · cited 1×
“In this scenario, MYC increases expression of the ARF tumor suppressor [183], which in turn destabilizes and inactivates the MDM2 Ub-ligase [184–186], thereby leading a rapid induction of p53 and activation of its broad tumorsuppressive apoptotic response [187].”
Backgroundc-Myc transactivation of LDH-A : Implications for tumor metabolism and growth
Shim, H., Dolde, C., Lewis, B. C., Wu, C.-S., Dang, G., Jungmann, R. A., Dalla-Favera, R., & Dang, C. V. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6658 · Cited by 1,092
A SARCOMA OF THE FOWL TRANSMISSIBLE BY AN AGENT SEPARABLE FROM THE TUMOR CELLS
Rous, P. (1911) · Journal of Experimental Medicine · doi:10.1084/jem.13.4.397 · Cited by 1,051
Eilers, M., & Eisenman, R. N. (2008) · Genes & Development · doi:10.1101/gad.1712408 · Cited by 927
c-Myc Can Induce DNA Damage, Increase Reactive Oxygen Species, and Mitigate p53 Function
Vafa, O., Wade, M., Kern, S., Beeche, M., Pandita, T. K., Hampton, G. M., & Wahl, G. M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00520-8 · Cited by 876
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer
Shachaf, C. M., Kopelman, A. M., Arvanitis, C., Karlsson, Å., Beer, S., Mandl, S., Bachmann, M. H., Borowsky, A. D., Ruebner, B., Cardiff, R. D., et al. (2004) · Nature · doi:10.1038/nature03043 · Cited by 874 · cited 1×
“In numerous mouse model systems, researchers have found that even transient inactivation of MYC leads to tumor collapse [294– 297] and even in settings where MYC activation is not the primary driving mutation [298].”
BackgroundDisruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis
Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J., & Cleveland, J. L. (1999) · Genes & Development · doi:10.1101/gad.13.20.2658 · Cited by 819 · cited 1×
“The role of ARF-MDM2-p53-mediated apoptosis in combatting the tumorigenic potential of MYC is reflected in the frequent loss of p53 in human cancers [190] and evidenced by data from mouse model systems showing that loss of this pathway collaborates with MYC to drive oncogenesis [191, 192] and that certain tumor-derive…”
BackgroundYeh, E., Cunningham, M., Arnold, H., Chasse, D., Monteith, T., Ivaldi, G., Hahn, W. C., Stukenberg, P. T., Shenolikar, S., Uchida, T., et al. (2004) · Nature Cell Biology · doi:10.1038/ncb1110 · Cited by 791
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724
The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins
McMahon, S. B., Van Buskirk, H. A., Dugan, K. A., Copeland, T. D., & Cole, M. D. (1998) · Cell · doi:10.1016/s0092-8674(00)81479-8 · Cited by 693 · cited 3×
“MbII is also important for precise regulation of the MYC protein; it contributes to MYC degradation [89, 90], integrates MYC activity with the health of ribosome biogenesis via competitive binding of TRRAP with the ribosomal L11 protein [91], and has been proposed to rein in MYC function by interacting with the SCFSkp…”
BackgroundThe 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer
Pomerantz, M. M., Ahmadiyeh, N., Jia, L., Herman, P., Verzi, M. P., Doddapaneni, H., Beckwith, C. A., Chan, J. A., Hills, A., Davis, M., et al. (2009) · Nature Genetics · doi:10.1038/ng.403 · Cited by 663
Revisiting Global Gene Expression Analysis
Lovén, J., Orlando, D. A., Sigova, A. A., Lin, C. Y., Rahl, P. B., Burge, C. B., Levens, D. L., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.10.012 · Cited by 616 · cited 2×
“Indeed, in this model, it is argued that past methods for normalizing transcriptomic data have led to the appearance of a set of MYC-repressed genes [262], but these are in fact nonresponding genes that merely seem to be repressed against the many thousands that are induced.”
BackgroundMethodX-Ray Structures of Myc-Max and Mad-Max Recognizing DNA
Nair, S. K., & Burley, S. K. (2003) · Cell · doi:10.1016/s0092-8674(02)01284-9 · Cited by 551
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy
Dörr, J. R., Yu, Y., Milanovic, M., Beuster, G., Zasada, C., Däbritz, J. H. M., Lisec, J., Lenze, D., Gerhardt, A., Schleicher, K., et al. (2013) · Nature · doi:10.1038/nature12437 · Cited by 541
The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc
McMahon, S. B., Wood, M. A., & Cole, M. D. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.2.556-562.2000 · Cited by 494
INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R., & Lowe, S. W. (1999) · Genes & Development · doi:10.1101/gad.13.20.2670 · Cited by 458 · cited 1×
“The role of ARF-MDM2-p53-mediated apoptosis in combatting the tumorigenic potential of MYC is reflected in the frequent loss of p53 in human cancers [190] and evidenced by data from mouse model systems showing that loss of this pathway collaborates with MYC to drive oncogenesis [191, 192] and that certain tumor-derive…”
BackgroundChou, T.-Y., Hart, G. W., & Dang, C. V. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.32.18961 · Cited by 453
Zhan, L., Rosenberg, A., Bergami, K. C., Yu, M., Xuan, Z., Jaffe, A. B., Allred, C., & Muthuswamy, S. K. (2008) · Cell · doi:10.1016/j.cell.2008.09.045 · Cited by 436 · cited 1×
“As discussed in the next section, mutant forms of MYC are prevalent in Burkitt’s lymphoma but are not widely seen in other cancers, and all evidence from cell- and animal-based studies is that expression of a pristine form of MYC is sufficient to promote tumorigenesis [24, 118–121].”
Backgroundc-Myc enhances protein synthesis and cell size during B lymphocyte development
Iritani, B. M., & Eisenman, R. N. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13180 · Cited by 364 · cited 2×
“The conundrum created by the subtlety of MYC’s transcriptional output is further deepened by the prospect that MYC could enhance transcription globally, either by broad effects on the phosphorylation status of RNA polymerase II [259] or by something as seemingly unrelated as increasing cell size [194], which in turn l…”
BackgroundHematopoietic stem cell function and survival depend on c-Myc and N-Myc activity
Laurenti, E., Varnum-Finney, B., Wilson, A., Ferrero, I., Blanco-Bose, W. E., Ehninger, A., Knoepfler, P. S., Cheng, P.-F., MacDonald, H. R., Eisenman, R. N., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.09.005 · Cited by 305
Hu, S., Balakrishnan, A., Bok, R. A., Anderton, B., Larson, P. E. Z., Nelson, S. J., Kurhanewicz, J., Vigneron, D. B., & Goga, A. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.04.012 · Cited by 245 · cited 1×
“MYC stimulates the expression of a broad set of genes involved in glucose uptake and glycolysis [207], and key glycolytic regulators such as LDH-A are activated by MYC in a variety of cell types [208].”
BackgroundMyc regulates keratinocyte adhesion and differentiation via complex formation with Miz1
Gebhardt, A., Frye, M., Herold, S., Benitah, S. A., Braun, K., Samans, B., Watt, F. M., Elsässer, H.-P., & Eilers, M. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200506057 · Cited by 118 · cited 1×
“Since that time, MYC proteins have been shown to repress a host of genes that—not surprisingly—tend to be those with antiproliferative or anticancer properties, such as cell cycle inhibitors [269], tumor-suppressive miRNAs [96], and cell adhesion molecules [270].”
Background
Cited by
MYC: Connecting selective transcriptional control to global RNA production
Kress, T. R., Sabò, A., & Amati, B. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3984 · Cited by 521
Evaluation of the use of therapeutic peptides for cancer treatment
Marqus, S., Pirogova, E., & Piva, T. J. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0328-x · Cited by 512
Therapeutic targeting of “undruggable” MYC
Llombart, V., & Mansour, M. R. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2021.103756 · Cited by 472
MYC protein interactors in gene transcription and cancer
Lourenco, C., Resetca, D., Redel, C., Lin, P., MacDonald, A. S., Ciaccio, R., Kenney, T. M. G., Wei, Y., Andrews, D. W., Sunnerhagen, M., et al. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00367-9 · Cited by 347
Interaction with WDR5 Promotes Target Gene Recognition and Tumorigenesis by MYC
Thomas, L. R., Wang, Q., Grieb, B. C., Phan, J., Foshage, A. M., Sun, Q., Olejniczak, E. T., Clark, T., Dey, S., Lorey, S., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.028 · Cited by 310
“, 2014), but it is clear that in vivo tumorigenesis by MYC depends on its chromatin-binding abilities (Tansey, 2014).”
InfluentialSelf-citation
Metadata
- Authors
- Tansey, W. P.
- Venue
- New Journal of Science
- Publisher
- Hindawi Limited
- Published
- 2014-02-02
- Volume
- 2014
- Pages
- 1-27
- ISSN
- 2090-8520 (ISSN-L)
- 2356-7740
- OpenAlex
- W2033119814
- Cited by
- 151
- References
- 36
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.